The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
The data, presented in Chicago at the annual meeting of the American Society of Clinical Oncology , show progression-free survival for the Trodelvy group of 5.5 months compared with 4 months for chemotherapy patients. At the study's first analysis, Trodelvy patients lived a median 13.9 months, compared to 12.3 months for the chemotherapy group — a difference that was not statistically significant.
Patients with hormone-sensitive, HER2-negative metastatic breast cancer are treated with endocrine therapy combined with targeted drugs. As the disease becomes resistant, treatment is limited to chemotherapies with increasingly short durations of benefit. But he expressed caution about potential competition from Enhertu — an AstraZeneca Plc drug that is being studied for breast cancer patients with low levels of HER2.
As expected, it will cost an arm or a leg to get one vial 😳
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: rapplerdotcom - 🏆 4. / 86 Read more »
Source: rapplerdotcom - 🏆 4. / 86 Read more »
Source: rapplerdotcom - 🏆 4. / 86 Read more »
Source: sunstaronline - 🏆 18. / 59 Read more »